Selective Induction of Cellular Toxicity and Anti-tumor Efficacy by N-Methylpiperazinyl Diarylidenylpiperidone and
Jesse M Mast1, John W Hinds1, Dan Tse1
1Departments of Radiology, Geisel School of Medicine, Dartmouth College, 1 Medical Center Drive, Lebanon, NH, 03756, USA.
Abstract:
Pancreatic adenocarcinoma is an aggressive cancer with poor clinical prognosis and limited therapeutic options. There is a significant lack of effective, safe, and targeted therapies for successful treatment of pancreatic cancer. In this report, we describe the anticancer efficacy of two novel compounds, N-methylpiperazinyl diarylidenylpiperidone (L-2663) and its pro-nitroxide conjugate (HO-4589) evaluated on human pancreatic adenocarcinoma (AsPC-1) cell line and xenograft tumor in mice. Using flow cytometry, we determined the effect of the L-2663 and HO-4589 drugs in inducing mitochondrial toxicity, triggering cell-cycle arrest, and apoptosis. EPR spectroscopy was used to quantify cellular uptake, metabolic conversion and stability of HO-4589 in cells and in vivo monitoring of tumor oxygenation as a function of growth. The results established different antiproliferative efficacy of the L-2663 and HO-4589 compounds, with a targeted action on cancer cells while being less toxic to noncancerous cells. The study may have important implications in the future designs of safe and effective chemotherapeutic agents for the treatment of pancreatic cancer.
Insights
Two novel compounds, L-2663 and HO-4589, show anticancer efficacy against pancreatic cancer by inducing cell death and cycle arrest. These agents target cancer cells with reduced toxicity to normal cells, offering potential for new pancreatic cancer therapies.
Area of Science:
- Oncology
- Pharmacology
- Biochemistry
Background:
- Pancreatic adenocarcinoma presents a significant clinical challenge due to its aggressive nature, poor prognosis, and limited treatment options.
- There is a critical unmet need for effective, safe, and targeted therapies for pancreatic cancer.
- Novel therapeutic strategies are essential for improving patient outcomes.
Purpose of the Study:
- To evaluate the anticancer efficacy of two novel compounds, N-methylpiperazinyl diarylidenylpiperidone (L-2663) and its pro-nitroxide conjugate (HO-4589).
- To assess the effects of these compounds on human pancreatic adenocarcinoma (AsPC-1) cells and in a mouse xenograft model.
- To investigate the mechanisms of action, including mitochondrial toxicity, cell-cycle arrest, and apoptosis.
Main Methods:
- Utilized flow cytometry to analyze drug-induced mitochondrial toxicity, cell-cycle arrest, and apoptosis in AsPC-1 cells.
- Employed Electron Paramagnetic Resonance (EPR) spectroscopy to quantify cellular uptake, metabolic conversion, and stability of HO-4589.
- Monitored in vivo tumor oxygenation using EPR spectroscopy in a mouse xenograft model.
Main Results:
- Demonstrated distinct antiproliferative efficacy for L-2663 and HO-4589 against pancreatic cancer cells.
- Confirmed targeted action of the compounds on cancer cells, with notably lower toxicity towards noncancerous cells.
- Established the cellular uptake, metabolism, and stability of HO-4589, along with its impact on tumor microenvironment.
Conclusions:
- L-2663 and HO-4589 exhibit promising anticancer properties for pancreatic cancer treatment.
- These compounds demonstrate a favorable therapeutic window, targeting cancer cells selectively.
- The findings support the potential development of these novel agents as safe and effective chemotherapeutic drugs for pancreatic cancer.
